JLE

Epileptic Disorders

MENU

Cutaneous adverse reactions associated with antiseizure medication: clinical characteristics and implications in epilepsy treatment Volume 23, numéro 3, June 2021

  • [1] Alsfouk B.A.A., Brodie M.J., Walters M., Kwan P., Chen Z. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurol. 2020;77:574-581. 5
  • [2] Botelho L.F.F., Porro A.M., Enokihara M.M.S.S., Tomimori J. Adverse cutaneous drug reactions in a single quaternary referral hospital. Int J Dermatol. 2016;55:e198-203.
  • [3] Diphoorn J., Cazzaniga S., Gamba C., Schroeder J., Citterio A., Rivolta A.L. Incidence, causative factors and mortality rates of Stevens – Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf. 2016;25:196-203.
  • [4] Borrelli E.P., Lee E.Y., Descoteaux A.M., Kogut S.J., Caffrey A.R. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the food and drug administration adverse event reporting system (FAERS). Epilepsia. 2018;59:2318-2323. 12
  • [5] Ardern-Jones M.R., Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2019;19:283-293.
  • [6] Arif H., Weintraub D., Koyfman S., Buchsbaum R., Weintraub D., Koyfman S. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68:1701-1709. 20
  • [7] Mockenhaupt M., Viboud C., Dunant A., Naldi L., Halevy S., Bavinck J.N.B. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44. 1
  • [8] Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609-611. 3
  • [9] Sassolas B., Haddad C., Mockenhaupt M., Dunant A., Liss Y., Bork K. ALDEN, an algorithm for assessment of drug causality in stevens-johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60-68. 1
  • [10] Kuyucu S., Caubet J.C. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 2018;6:1879-1891.e1. 6
  • [11] Mani R., Monteleone C., Schalock P.C., Truong T., Zhang X.B., Wagner M.L. Rashes and other hypersensitivity reactions associated with antiepileptic drugs: a review of current literature. Seizure. 2019;71:270-278.
  • [12] Frey N., Bodmer M., Bircher A., Rüegg S., Jick S.S., Meier C.R. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. Epilepsia. 2017;58:2178-2185. 12
  • [13] Hyson C., Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci. 1997;24:245-249. 3
  • [14] Hirsch L.J., Arif H., Nahm E.A., Buchsbaum R., Resor S.R., Bazil C.W. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology. 2008;71:1527-1534. 19
  • [15] Pichler W.J., Adam J., Daubner B., Gentinetta T., Keller M., Yerly D. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am. 2010;94:645-664. 4
  • [16] Pichler W.J., Srinoulprasert Y., Yun J., Hausmann O. Multiple drug hypersensitivity. Int Arch Allergy Immunol. 2017;172:129-138. 3
  • [17] Hosohata K., Inada A., Oyama S., Niinomi I., Wakabayashi T., Iwanaga K. Adverse cutaneous drug reactions associated with old- and new-generation antiepileptic drugs using the Japanese pharmacovigilance database. Clin Drug Investig. 2019;39:363-368. 4
  • [18] Blaszczyk B., Szpringer M., Czuczwar S.J., Lason W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacol Reports. 2013;65:399-409. 2
  • [19] Brazil Ministry of the Economy. Portal Brasileiro de Dados Abertos [Internet]. 2020 [cited 2020 Oct 28]. Available from: https://dados.gov.br/.
  • [20] de Freitas-Lima P., de Oliveira Baldoni A., Alexandre V., Pereira L.R.L., Sakamoto A.C. Drug utilization profile in adult patients with refractory epilepsy at a tertiary referral center. Arq Neuropsiquiatr. 2013;71:856-861. 11
  • [21] Guilhoto LMDFF, Alexandre V., Martins H.H., Dos Santos C.M., Lin K., Da Silva A.R.C.O. Há riscos na utilização de diferentes formulações de drogas antiepilépticas? Relato da ABE através de entrevista de pessoas com epilepsia. J Epilepsy Clin Neurophysiol. 2009;15:41-49. 1
  • [22] Andersson P.L., Fick J., Rännar S. A multivariate chemical similarity approach to search for drugs of potential environmental concern. J Chem Inf Model. 2011;51:1788-1794. 8
  • [23] Zhang Y., Geißen S.U., Gal C. Carbamazepine and diclofenac: removal in wastewater treatment plants and occurrence in water bodies. Chemosphere. 2008;73:1151-1161. 8
  • [24] Benotti M.J., Trenholm R.A., Vanderford B.J., Holady J.C., Stanford B.D., Snyder S.A. Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water. Environ Sci Techno. 2009;43:597-603. 3
  • [25] Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res. 1998;32:3245-3260. 11
  • [26] Guedes-Alonso R., Montesdeoca-Esponda S., Pacheco-Juárez J., Sosa-Ferrera Z., Santana-Rodríguez J.J. A survey of the presence of pharmaceutical residues in wastewaters. Evaluation of their removal using conventional and natural treatment procedures. Molecules. 2020;25:1639. 7
  • [27] Ramirez A.J., Brain R.A., Usenko S., Mottaleb M.A., O’Donnell J.G., Stahl L.L. Occurrence of pharmaceuticals and personal care products in fish: results of a national pilot study in the United States. Environ Toxicol Chem. 2009;28:2587-2597. 12
  • [28] Simper G.S., Hò G.T., Celik A.A., Huyton T., Kuhn J., Kunze-Schumacher H. Carbamazepine-mediated adverse drug reactions: CBZ-10,11-epoxide but not carbamazepine induces the alteration of peptides presented by HLA-B-15:02. J Immunol Res. 2018;2018:e1-12.
  • [29] Hirsch L.J., Weintraub D.B., Buchsbaum R., Spencer H.T., Straka T., Hager M. Predictors of lamotrigine-associated rash. Epilepsia. 2006;47:318-322. 2
  • [30] Alvestad S., Lydersen S., Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80:194-200. 2–3
  • [31] Crisafulli G., Franceschini F., Caimmi S., Bottau P., Liotti L., Saretta F. Mild cutaneous reactions to drugs. Acta Biomed. 2019;90:36-43. 3
  • [32] Lerch M., Pichler W.J. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol. 2004;4:411-419. 5
  • [33] Hoetzenecker W., Nägeli M., Mehra E.T., Jensen A.N., Saulite I., Schmid-Grendelmeier P. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol. 2016;38:75-86. 1
  • [34] Casagranda A., Suppa M., Dehavay F., del Marmol V. Overlapping DRESS and Stevens-Johnson syndrome: case report and review of the literature. Case Rep Dermatol. 2017;9:1-7.
  • [35] Horcajada-Reales C., Pulido-Pérez A., Suárez-Fernández R. Severe cutaneous drug reactions: do overlapping forms exist? Actas Dermosifiliogr. 2018;107:23-33. 1
  • [36] Pinto Gouveia M., Gameiro A., Coutinho I., Pereira N., Cardoso J.C., Gonçalo M. Overlap between maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms among cutaneous adverse drug reactions in a dermatology ward. Br J Dermatol. 2016;175:1274-1283. 6
  • [37] Manriquez J., Andino-Navarrete R., Cataldo-Cerda K., Downey C., Berroeta D. Progression of drug exanthemas to serious drug eruptions: a retrospective review identifying early determinants. Australas J Dermatol. 2016;57:e83-e87. 3
  • [38] Weinkle A., Pettit C., Jani A., Keller J., Lu Y., Malachowski S. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation - a retrospective chart review. J Am Acad Dermatol. 2019;81:749-757. 3
  • [39] Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Guerreiro C., Kälviäinen R. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-563. 3